New hope for lung cancer patients who stopped responding to standard therapy
NCT ID NCT07518160
First seen Apr 11, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study tests two experimental drugs, JS212 and JS111, together in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to standard targeted therapy. About 35 adults will join to find the safest dose and see if the combination shrinks tumors. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED, METASTATIC, OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.